BioSpace News Archive

Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).

Ocutrx Technologies, Inc. an augmented/extended reality and surgical device manufacturing company focused on transforming healthcare technology, announced today the issuance of its fifth patent by the U.S. Patent & Trademark Office. The fifth patent covers a Macular Visual Field (MVF) test administered while the user is wearing the Oculenz™ AMD AR/XR headset.

PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy, is pleased to announce the appointment of Ojas A. Buch as President of the Americas.

Strata to present data on comprehensive genomic and transcriptomic profiling in patients with advanced solid tumors

Elite Pharmaceuticals, Inc. (OTCBB:ELTP) announced today that its distribution and marketing partner Prasco, LLC has launched Elites generic Loxapine capsules.

The British success story continues apace as the biggest names in food, cosmetics, personal care & agritech globally look to confirm the positive biological impact of next-generation products, and play their part in solving real-world challenges capitalising on the worldwide microbiome megatrend

Life Spine Announces FDA 510(k) Clearance for the PROLIFT ® Lateral HELO Fixation System

Invectys, Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced the appointment of Praveen Tyle, PhD, as President & CEO and election to its Board of Directors.

The Lawrence J. Ellison Institute for Transformative Medicine of USC is pleased to announce the formation of a Policy Department and the hire of Gabriel Seidman, DrPH, as Director of Policy.

Biotech Veteran Brings Deep Scientific and Clinical Leadership to Immune-Onc as the Company Expands Clinical Development of its Novel Myeloid Checkpoint Inhibitors Recent $6M Award from the California Institute for Regenerative Medicine (CIRM) Will Further Accelerate Clinical Development of IO-202, a First-in-Class LILRB4 Antagonist Antibody